Evidence map›Paper›PMID 28844013›Full record

ArticleDrug and alcohol dependence2017

Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.

Jermaine D Jones, Jeanne M Manubay, Shanthi Mogali, Verena E Metz, Gabriela Madera, Suky Martinez, Mudassir Mumtaz, Sandra D Comer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Potential therapeutic targets for the treatment of opioid abuse and pain.Advances in pharmacology (San Diego, Calif.) · 2022
    Review
  5. Article
  6. Prescription Opioid Misuse Motives in US Older Adults.Pain medicine (Malden, Mass.) · 2020
    Article
  7. Article
  8. Article
  9. Emerging Evidence for Cannabis' Role in Opioid Use Disorder.Cannabis and cannabinoid research · 2018
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jermaine D JonesDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA. Electronic address: Jermaine.Jones@NYSPI.Columbia.edu.
Jeanne M ManubayDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Shanthi MogaliDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Verena E MetzDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Gabriela MaderaDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Suky MartinezDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA; Translational Research Training Program in Addiction, City College of New York, 160 Convent Avenue, New York, NY 10031, USA.
Mudassir MumtazDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA; Translational Research Training Program in Addiction, City College of New York, 160 Convent Avenue, New York, NY 10031, USA.
Sandra D ComerDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Columbia University · USCity College of New York · US

Funding

Translational Research Training on Addictions for Racial/Ethnic MinoritiesR25DA035161 · NIDA · CITY COLLEGE OF NEW YORK · PI DENISE AIMEE HIEN, Lesia Monique Ruglass · 2013 to 2026
$4.4M
Contribution of Various Genetic Polymorphisms to Oxycodone's Abuse LiabilityK01DA030446 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI JONES, JERMAINE D · 2011 to 2015
$907k
NIDA NIH HHS K01 DA030446NIDA NIH HHS R25 DA035161
6 · The paper itself

Abstract

backgroundThis study sought to determine the relative importance of a range of Bup/Nx doses compared to Bup alone in producing subjective and reinforcing effects.

methodsHeroin-using volunteers (n=13) were transitioned onto daily oral hydromorphone (40mg). Laboratory sessions assessed the reinforcing and subjective effects of intravenous (IV) doses of Bup (1.51, 2.16, 6.15, and 8.64mg) and Bup/Nx (1.51/0.44, 2.16/0.61, 6.15/1.71, and 8.64/2.44mg). Placebo (Pbo), heroin (25mg) and Nx (0.3mg) were tested as neutral, positive, and negative controls, respectively.

resultsIV Bup alone was self-administered substantially less than IV heroin, though the two largest doses of Bup produced positive subjective effects, drug "Liking" (0-100mm), which were comparable to heroin (mean difference: Heroin vs Bup 6.15mg: -3.4mm, Heroin vs Bup 8.64mg: -11.3mm). All indicators of abuse potential seen with IV Bup alone were substantially decreased with the addition of Nx. All Bup/Nx combinations produced ratings of aversive effects, "Bad", which were comparable to, or greater than IV, Nx. On three of the four measures of aversive effects, the largest difference is seen with the 8.64 vs 8.64/2.44 condition.

conclusionsThis study further demonstrates the ability of the Bup/Nx combination to deter IV use. Although none of the Bup/Nx combinations showed indications of abuse potential, formulations with larger absolute Nx, may be less abusable as they precipitate a greater degree of withdrawal.

Indexed as

BuprenorphineBuprenorphine, Naloxone Drug CombinationHeroinHumansInjections, IntravenousNaloxoneOpioid-Related DisordersReinforcement, PsychologyBuprenorphineBuprenorphine, Naloxone Drug CombinationHeroinNaloxoneAbuse liabilityBuprenorphineIntravenousOpioidSelf-administration

Identifiers

PMID28844013
PMCPMC10071507
OpenAlexW2737962821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.